Ruxolitinib for essential thrombocythemia? - Wikidata - awgldk - TriplyDB

Ruxolitinib for essential thrombocythemia?

Ruxolitinib for essential thrombocythemia?

http://www.wikidata.org/entity/Q49727337

about

Ruxolitinib for essential thrombocythemia?

http://www.wikidata.org/entity/Q49727337

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ruxolitinib for essential thrombocythemia?

@en

Ruxolitinib for essential thrombocythemia?

@nl

type

label

Ruxolitinib for essential thrombocythemia?

@en

Ruxolitinib for essential thrombocythemia?

@nl

prefLabel

Ruxolitinib for essential thrombocythemia?

@en

Ruxolitinib for essential thrombocythemia?

@nl

P1433

Q49727337-2BF1829C-3EDB-435A-9456-69FE2C1ECB4B

P1476

Q49727337-74C1FE85-EA7E-4C06-9FE6-CA4350B9C094

P2093

Q49727337-0C04EDC0-98D8-4AEC-8060-E0572B466D27

P2860

Q49727337-21193297-55CD-43B2-87ED-1ECF7BA3283D

Q49727337-47457B5E-7093-4846-A693-7B7192C03D01

Q49727337-68BEAB29-D768-422E-9769-C7707E3C40A6

Q49727337-886F380C-6709-4582-96FC-A91970098D45

Q49727337-9C110D76-04DF-4E5D-BF27-3556F15A23A1

Q49727337-A691DB62-D59C-4EE5-A86A-F078A796CF1E

Q49727337-E44D91E8-69D7-4CD9-9E7D-75540364AC90

Q49727337-EE2DF658-E1C9-4AAD-8386-F38F1748D1D8

P304

Q49727337-25389CF4-9CDB-440E-B4D2-ECF0A98ACF2C

P31

Q49727337-EF9E5FEF-10C3-4157-AC5F-42DAAD05346B

Q49727337-a72e9d72-6e21-4a0f-a562-497f587c4727

P356

Q49727337-5F348B52-1CCB-403D-A095-A209203BF498

P433

Q49727337-5D10D998-F9D5-4302-B32F-3D0588737368

P478

Q49727337-584955DE-B6F6-435A-870D-0D58AB88B2F3

P50

Q49727337-F5ED2C95-A0E2-4551-A2EE-82564164EE6A

P577

Q49727337-11870817-C327-448C-9660-2E9446167A1B

P698

Q49727337-F10674CC-CB29-416D-A47C-91A2B81414E1

P932

Q49727337-1E99662E-7E10-4720-8C3F-63D50FFD241D

P356

ONCOSCIENCE.373

P1433

P1476

Ruxolitinib for essential thrombocythemia?

@en

P2093

Prithviraj Bose

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

P304

148-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOSCIENCE.373

http://www.w3.org/2001/XMLSchema#string

P433

11-12

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Srdan Verstovsek

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29344542

http://www.w3.org/2001/XMLSchema#string

P932

5769968

http://www.w3.org/2001/XMLSchema#string